Signed Olopatadine HCL Oph Sol SPE2D223D0007 P00011 Mfg NDC Change.pdf

X

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE

J

2. AMENDMENT/MODIFICATION NO.

P00011

3. EFFECTIVE DATE

See Blk. 16C

4. REQUISITION/PURCHASE REQ. NO.

See Block 14

5. PROJECT NO. (If applicable)

6. ISSUED BY CODE SPE2D2 7. ADMINISTERED BY (If other than Item 6) CODE SPE2D2

DLA TROOP SUPPORT DLA TROOP SUPPORT

MEDICAL SUPPLY CHAIN FSGB

700 ROBBINS AVENUE

PHILADELPHIA PA 19111

USA

MEDICAL SUPPLY CHAIN (FSJ)

700 ROBBINS AVENUE

PHILADELPHIA PA 19111-5092

USA

Initiator: Kyle Lewicki DKL0040 Tel: 445-737-0977 Email: Kyle.Lewicki@dla.mil

8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code) (X) 9A. AMENDMENT OF SOLICITATION NO.

GOLDEN STATE MEDICAL SUPPLY, INC. 9B. DATED (SEE ITEM 11)

DBA GOLDEN STATE MEDICAL SUPPLY INC

5187 CAMINO RUIZ

CAMARILLO CA 93012-8601 10A. MODIFICATION OF CONTRACT/ORDER NO.

USA

X

SPE2D2-23-D-0007

10B. DATED (SEE ITEM 13)

2023 FEB 15

CODE 1HT23 FACILITY CODE

11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers is extended, is not extended.

Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:

(a) By completing Items 8 and 15, and returning copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted;

or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

12. ACCOUNTING AND APPROPRIATION DATA (If required)

13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS,

IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

CHECK ONE A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO.

IN ITEM 10A.

B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES ( such as changes in paying office, appropriation date, etc. ) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103 (b).

X

C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

FAR 52.212-4(c)

D. OTHER (Specify type of modification and authority)

E. IMPORTANT: Contractor is not, is required to sign this document and return 1 copies to the issuing office.

14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

See Continuation Sheet

Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

15A NAME AND TITLE OF SIGNER (Type or print) 16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)

15B. CONTRACTOR/OFFEROR 15C. DATE SIGNED 16B. UNITED STATES OF AMERICA

(Signature of Contracting Officer)

16C. DATE SIGNED

(Signature of person authorized to sign)

NSN 7540-01-152-8070

Previous edition unusable

STANDARD FORM 30 (REV. 10-83)

Prescribed by GSA FAR (48 CFR) 53.243

Brian Current, VP Pricing & Commerical Strategy

4/29/2026 mailto:Kyle.Lewicki@dla.mil

CONTINUATION SHEET REFERENCE NO. OF DOCUMENT BEING CONTINUED:

SPE2D2-23-D-0007 / P00011

PAGE 2 OF 2 PAGES

Reference: Email chain dated 1/13/2026 and 4/22/2026 between Trudy Nickelson/Brian Current (GSMS) and Kyle Lewicki (DLA Troop Support)

1. This modification pertains to Olopatadine HCL 0.1% Ophthalmic Solution 5ML Bottle under National Contract SPE2D2-23-D-0007. Current NDC valid through 5/31/2026 for Olopatadine HCL 0.1% Ophthalmic Solution 5ML Bottle. New NDC added to contract effective June 1, 2026. No changes to pricing.

2. This modification changes the Manufacturer, Place of Performance and NDC for Olopatadine HCL 0.1% Ophthalmic Solution 5ML Bottle from Apotex Inc. to SamChunDang Pharm Co., Ltd. (Contracted Manufacturing Organization) CMO for Glenmark Therapeutics Inc., USA effective June 1, 2026 for the following line items only:

CHANGES APPLY TO THE FOLLOWING DESCRIPTIONS

CURRENT NDC IN EFFECT UNTIL May 31, 2026

51407-0663-05 Olopatadine HCL 0.1% Ophthalmic Solution 5ML Bottle Unit Price $10.16

NEW NDC ADDED TO CONTRACT EFFECTIVE JUNE 1, 2026

51407-0938-05 Olopatadine HCL 0.1% Ophthalmic Solution 5ML Bottle Unit Price $10.16

3. The Abbreviated New Drug Application (ANDA) holder is Glenmark Therapeutics Inc., USA under ANDA 200810 for Olopatadine HCL 0.1% Ophthalmic Solution 5ML Bottle.

4. Place of Performance is changed for Olopatadine HCL 0.1% Ophthalmic Solution 5ML Bottle as follows:

New Place of Performance:

SamChunDang Pharm Co Ltd 71 Jeyakogondan-2Gil Huangnam-eup, Gwaseong, 19622 Korea, South (KOR)

“TABLETS, CAPSULES AND PILLS”, “PACKAGING” AND “PACKING” for Olopatadine HCL 0.1% Ophthalmic Solution 5ML Bottle.

Complete Address of Facility SamChunDang Pharm Co Ltd 71 Jeyakogondan-2Gil Huangnam-eup, Gwaseong, 19622 Korea, South (KOR)

Point of Contact Rick Cunningham 720-339-9733

PACKAGING

Complete Address of Facility SamChunDang Pharm Co Ltd 71 Jeyakogondan-2Gil Huangnam-eup, Gwaseong, 19622 Korea, South (KOR)

Point of Contact Rick Cunningham 720-339-9733

PACKING

Complete Address of Facility SamChunDang Pharm Co Ltd 71 Jeyakogondan-2Gil Huangnam-eup, Gwaseong, 19622 Korea, South (KOR)

Point of Contact Rick Cunningham 720-339-9733

5. No Administrative or Consideration Costs will be assessed for issuing this modification.

6. All other terms and conditions remain unchanged.

16C DATE SIGNED: 4/30/2026